In the SSTR2-negative pancreatic and non-small lung cell cancer models of Zou and colleagues, re-expression of SSTR2 in the cancer cells led to significantly impaired tumor growth which was aggravated in a dose-dependent manner by application of octreotide and its derivate vapreotide (RC-160, [27]). The gene discussed is SSTR2; the disease is non-small cell lung carcinoma.